Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market – Market Insights
Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. This helps to restore DNA when it is damaged by many factors such as exposure to UV radiation, some anti-cancer drugs and others. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in the DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency of other DNA repair pathways.
Furthermore, PARP inhibitors play an effective maintenance role in current cancer treatments owing to their therapeutic effect on ovarian cancer. According to the World Ovarian Cancer Coalition statistics of 2018, there are around 600,000 women diagnosed with an ovarian cancer for a period of 5 years.
The global PARP (Poly ADP-Ribose Polymerase) inhibitor market was valued at US$ 887.7 Mn in 2018, and is expected to exhibit a CAGR of 32.4% over the forecast period (2019–2027).
Figure 1. Global PARP Inhibitor Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing research and development activities by market players are expected to increase application of PARP inhibitors
Currently, PARP is indicated for treatment of ovarian cancer and breast cancer. However, researchers are focused on expanding the application of PARP inhibitors. For instance, in December 2018, University of Michigan Rogel Cancer Center planned Phase II trials of the investigational drug combination of olaparib and AZD6738 for treatment of metastatic castration-resistant prostate cancer.
In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II studies to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometrial ovarian cancer. The study is expected to be completed in January 2022.
In April 2019, Pfizer, Inc., received positive feedback from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for TALZENNA (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor indicated for treatment in locally advanced (LA) or metastatic breast cancer (MBC).
Moreover, delays in regulatory approvals can result in delayed marketing of the product, which can affect the revenue of the manufacturer. Similarly, delay in post approval of the drug for other therapeutic indications results in increasing clinical trials costs and can impact the labelling and approval status of currently marketed products. Thus, these factors are expected to hamper the PARP inhibitor market growth.
Figure 2. Global PARP Inhibitor Market Share (%), by Application
Source: Coherent Market Insights Analysis (2019)
Increasing approvals of innovative drugs molecules in PARP inhibitor market
In the recent past, several key players in the market have received approvals for their PARP inhibitor molecules which is expected to create a lucrative environment for growth of global PARP inhibitors market in the near future.
In January 2018, AstraZeneca PLC received approval from the Japanese Ministry of Health, Labour and Welfare for Lynparza (olaparib) tablets indicated as maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer. Lynparza is the first approved poly ADP-ribose polymerase (PARP) inhibitor in Japan.
In October 2018, Pfizer, Inc., received the U.S. Food and Drug Administration approval for TALZENNA (talazoparib), a (PARP) inhibitor indicated for treatment in locally advanced (LA) or metastatic breast cancer (MBC).
In April 2018, Clovis Oncology, Inc. received the U.S. Food and Drug Administration approval for Rubraca (rucaparib) tablets, a (PARP) inhibitor indicated for treatment of recurrent ovarian cancer.
Moreover, several key players in the market are focusing on strategic mergers and acquisition strategies for expanding their product portfolios. For instance, in January 2019, GlaxoSmithKline plc, acquired TESARO, Inc. for around US$ 5.1 billion. TESARO, Inc. has developed the approved product Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor indicated for ovarian cancer. The acquisition is expected to increase the application of Zejula for multiple cancer treatments.
Major players operating in the global PARP inhibitor market include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline Plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol Myers Squibb, Merck KGaA, Genentech, Inc., Artios Pharma, Repare Therapeutics Inc., Sierra Oncology, Inc., KaryopharmTherapeutics Inc., Ono Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
PARP inhibitors are drugs which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors are developed for treating several diseases, the most important one is cancer. Several types of cancers rely on PARP enzymes than regular cells, which makes these inhibitors an effective mode of treating cancers. PARP inhibitors are used to treat a subset of ovarian cancer. Currently, 3 PARP inhibitors have been approved for use in ovarian cancer patients who have undergone 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016, and Niraparib in 2017. Furthermore, several PARP inhibitors which are currently in later stages of development have shown promising results in recently released clinical trials data.
The global PARP inhibitors market is driven by product developments, increasing number of positive results, as well as availability of novel therapies in the market. Companies such as Pfizer, AstraZeneca and Tesaro, Inc. have a robust pipeline of PARP inhibitors and several ongoing trials of products are scheduled to be completed by 2022. These factors are expected to propel growth of the market over the forecast period. However, side effects associated with the drugs and drug resistance among patients are some of the factors that are expected to hamper the market growth.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 36 market data tables and 30 figures on "PARP Inhibitor Market” - Global forecast to 2027.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.